GustafsonH., JohanssonB., EdsmyrF.: Peyronie's disease (Induratio penis plastica) experience of local treatment with Orgotein. Manoscritto in corso di pubblicazione su Europ. Urol.
3.
Meyer deSchmid J. J., LievainO., AttalM.: citati da Capra e Fischetti.(1)
4.
ChauvinH. F., SivanA.: citati da Capra e Fischetti.(1)
5.
UsaiE., PinnaA.: Aspetti uroandrologici. Relazione al 1° Congr. Naz. Soc. It. Androl., Pisa 7–9 aprile 1978, pag. 357–376, Pacini Editore.
6.
BianchiF.: L'operazione di Devine nell'induratio penis plastica. Urologia, 42; 184 (1975).
7.
MoralesA., BruceF.: The treatment of Peyronie's disease with parathyroid hormone. J. Urol., 114; 901 (1975).
MarbergerH., HuberW., BartschG., SchulteT., SwobodaP.: Orgotein, a new anti-inflammatory metalloprotein drug. Evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Intern. Urol. & Nephrol., 6; 61 (1974).
10.
MartinC. L.: Long time study of patients with Peyronie's disease treated with irradiation. Amer. J. Roentgenol., 114; 492 (1972).
11.
HelvieW. W., HochsnerS. F.: Radiation therapy in Peyronie's disease. South Med. J., 65; 1192 (1972).
FurlowW. L., SwensonH. E.Jr., LeeR. E.: Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J. Urol., 114; 69 (1975).
14.
FrankI. N., ScottW. W.: citati da Capra e Fischetti.(1)
15.
LowsleyC. S., BoyceW. H.: Further experience with an operation for the cure of Peyronie's disease. J. Urol., 63; 888 (1950).
16.
PoutasseE. F.: Peyronie's disease. J. Urol., 107; 419 (1972).
17.
ByströmJ., AlfthanO., JohansonB., KörlofB.: Induratio penis plastica (Peyronie's disease). Results after excision and dermo-fat grafting. Scand. J. Plast. Reconstr. Surg., 7; 137 (1973).
18.
DevineC. J.Jr., HortonC. E.: Surgical treatment of Peyronie's disease with a dermal graft. J. Urol., 111; 44 (1974).
19.
PearmanR. O.: Insertion of a silastic penile prosthesis for the treatment of organic sexual impotence. J. Urol., 107; 802 (1972).
20.
RazS., de KernionJ. B., KaufmanJ. J.: Surgical treatment of Peyronie's disease: a new approach. J. Urol., 117; 598 (1977).
21.
EdsmyrF., HuberW., MenanderK. B.: Orgotein efficacy in ameliorating side effects due to radiation therapy. I: Double-blind, placebo-controlled trial in patients with bladder tumors. Curr. Ther. Res., 19; 198 (1976).
22.
Menander-HuberK. B., EdsmyrF., HuberW.: Orgotein (superoxide dismutase): a drug for the amelioration of radiationinduced side effects. A double-blind, placebo-controlled study in patients with bladder tumours. Urol. Res., 6; 255 (1978).
23.
EdsmyrF., Menander-HuberK. B., HuberW.: Orgotein efficacy in ameliorating side effects due to radiation therapy. In: Bladder tumours and other topics in Urological Oncology, MacalusoM. Pavone, SmithP. H., EdsmyrF. eds., pag. 21. Life Sciences. Series Editor Antonino Zichichi, 1979.
24.
MarbergerH., BartschG., HuberW., MenanderK. B., SchulteT. L.: Orgotein: a new drug for the treatment of radiation cystitis. Curr. Ther. Res., 18; 466 (1975).
25.
SellmanA., Menander-HuberK. B.: citati da Menander-HuberK. B., HuberW., in: Superoxide and superoxidismutases. MichelsonA. M., CordJ. M. and FridovichI. eds., pag. 537. Academic Press, London1977.
26.
Lund-OlesenK., MenanderK. B.: Orgotein: A new anti-inflammatory metalloprotein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease. Curr Ther. Res., 16; 706 (1974).
27.
SantiniR.: Fibrosite dei corpi cavernosi, in: BezziE.: Urologia, pag. 700. UTET, Torino 1974.